FDA warns GLP-1 drugs carry potential risk of rare eye condition
The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition and required pharmaceutical companies to inform patients and doctors. The condition is non-arteritic anterior ischemic optic neuropathy (NAION), sometimes called an "eye stroke," caused by insufficient blood flow to the optic nerve. It typically causes sudden vision loss and, in severe cases, can lead to blindness; there are no proven treatments. These drugs include Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound.
In 40 seconds
- The FDA requires pharmaceutical companies to inform patients and doctors about the eye risk of GLP-1 drugs.
- The condition is non-arteritic anterior ischemic optic neuropathy (NAION), known as "eye stroke."
- NAION is caused by insufficient blood flow to the optic nerve and can cause sudden vision loss or blindness.
IASummary generated by artificial intelligence from a story by STAT. It may contain errors: the original source prevails.





Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.